banner-meds2.jpg

COVID-19 DATA RESOURCES

*Last updated on February 25, 2022

A resource gathering relevant open data sources of research and development, intellectual property and pricing related to COVID-19. This page is work in progress and will be updated regularly.

THEMES

Research and Development
Intellectual Property and Access
Pricing, procurement, distribution and manufacturing
Other
boxe-horizontale.jpg

Contribute to improve and update this page!

We particularly welcome suggestions on additional data sources.

RESEARCH AND DEVELOPMENT

  • WHO Research Database: The World Health Organization is gathering the latest scientific findings and knowledge on coronavirus disease (COVID-19) and compiling it in a database. It’s updated daily, downloadable and searchable with filters. It is organized in 5 main areas:

    • Update on research activities for novel coronavirus, which links to the R&D Blueprint page on COVID-19 providing information on research activity and prioritization of R&D, including a Research Roadmap.

    • International Clinical Trial Registry Platform, which allows downloading a file with all COVID-19 trials from the WHO ICTRP database.

    • COVID-19 Emergency Use Listing Procedure (EUL), provides information regarding WHO prequalification of in vitro diagnostics to detect SARS-CoV-2 and a list of products eligible for procurement.

    • Solidarity Clinical Trial for COVID-19 treatments, with general information on the international clinical trial to help find an effective treatment for COVID-19, launched by the World Health Organization and partners.

    • Accelerating a safe and effective COVID-19 vaccine, which includes a landscape of COVID-19 candidate vaccines.

Clinical Trials

  • Clinicaltrials.gov: Provides information on listed clinical studies related to the coronavirus disease (COVID-19). Also allows to search for U.S. Federally-funded clinical studies related to COVID-19ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine and gathers information of privately and publicly funded clinical studies conducted around the world.

  • EU Clinical Trials Register: The European Union Clinical Trials Register for COVID-19 provides information on study protocol and results information on: interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA); and clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.​

  • COVID-evidence: Updated database by the University of Basel with information about worldwide planned, ongoing, and completed trials on any intervention to treat or prevent SARS-CoV-2-infections.​​​

  • ICON Coronavirus Observatory: This page provides aggregate, updated news on coronavirus and COVID-19 clinical trials. It utilises AI analysis and data visualisation for COVID-19 news and social media, providing updates on the latest clinical trials, with insights into trending topics driving Coronavirus reporting.

  • COVID-19 Vaccine Tracker: Resource by the McGill University, tracking COVID-19 vaccines under development, including details of clinical trials and approvals.

​Treatment, Vaccines, Diagnostics

  • PCR - The pipeline of COVID-19 therapeutics, vaccines and diagnostics: Policy Cures Research's "dashboard provides an overview of the global pipeline of potential new vaccines, therapeutics and diagnostics currently under investigation for COVID-19. The interactive sunburst on the left is linked to the table below, allowing stratification by product type, technology, target and R&D stage."

  • IFPMA - Novel coronavirus (COVID-19) – Industry’s R&D efforts: The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has a dedicated page compiling R&D efforts of biopharmaceutical companies related to COVID-19. It has information on treatment, vaccine and diagnostics already approved or in different stages of development.​

  • Healthcare innovations to combat COVID-19: Artis Ventures compiled a database of diagnostics, treatments and vaccines already approved and under development for COVID-19, providing a snapshot and detailed information on each area.

  • COVID-19 Pipeline: COVID-19 Pipeline offers concise overviews and analyses of key research areas, including “Epidemiology and Natural History”, “Molecular Virology”, “Diagnostics and Serology”, “Prevention (PrEP and vaccines)” and “Treatment”. A collaborative project of the COVID-19 Working Group NY, the PrEP4All Collaboration, and Treatment Action Group - TAG.

  • Coronavirus Antiviral Research Database: A database by Stanford University with information on antiviral therapy, susceptibility and variants, along with other publications and educational material.

  • Coronavirus Drug and Treatment Tracker: The New York Times provides an updated list of the most-talked-about treatments for the coronavirus and a summary of the available evidence about their effectiveness.  Treatments are labeled as: "Widely used",  "Promising evidence", "Tentative or mixed evidence", "Not promising" or "Pseudoscience or fraud".

  • MetaEvidence COVID-19: Live meta-analysis and evidence synthesis of potential therapies for COVID-19, including a summary of preliminary results - a project run by the University Lyon-1 and Hospices Civils de Lyon. ​​​​​​

  • COVID-19 Treatment and Vaccine Tracker: The Milken Institute is tracking the development of treatments and vaccines for COVID-19 (coronavirus). It provides an aggregation of publicly-available information from validated sources, including a product-based perspective in downloadable pdf format.​

  • COVID-19 Vaccine Tracker: A weekly updated tracker by the RAPS - Regulatory Affairs Professionals Society providing information on the major vaccine candidates approved and in development for the prevention of COVID-19.


Funding and Incentives for R&D

  • COVID-19 Vaccine R&D Investments: A resource gathering publicly available data on investments for COVID-19 vaccines R&D. Developed by the Global Health Centre, Graduate Institute of Geneva.

  • EU Coronavirus research and innovation: European Union webpage with supported research and innovation projects and initiatives to tackle the spread of coronavirus and preparedness for other outbreaks.​

  • COVID-19 Research Project Tracker: A live database of funded research projects across the world relating to COVID-19, developed by the UK Collaborative on Development Research (UKCDR) and Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), containing information on more than 11,000 projects across 134 countries.

  • UAEM Public Medicines for COVID-19: Universities Allied for Essential Medicine (UAEM) developed a database tracking public investment in international COVID-19 research and development for COVID-19 vaccines, therapeutics and diagnostics.

  • Devex - Funding the response to COVID-19: The media platform Devex developed an interactive tool with global COVID-19 funding data from public, private and philanthropic sectors, including a breakdown by focus areas such as research, vaccine/treatment and manufacturing.​​

  • R&D response to COVID-19 pandemic: A live blog by Science Business compiling information about R&D what governments, funders, companies, universities, associations and scientists are doing related to COVID-19.

  • KEI COVID-19 Contracts: Knowledge Ecology International (KEI) provides links to copies of the contracts entered into by the US government, the European Union and inter-company agreements for technologies to combat the COVID-19 pandemic.


R&D Partnerships 

​​

  • COVID-19 Clinical Research Coalition: A coalition of R&D organizations founded with the aim to accelerate COVID-19 research in resource-limited settings and promote the greatest possible sharing of research knowledge and data.

INTELLECTUAL PROPERTY AND ACCESS

IP Policies

 

  • WIPO COVID-19 IP Policy Tracker: The World Intellectual Property Organization - WIPO page provides information on legislative and regulatory measures and voluntary actions regarding COVID-19.

Patent Information

  • PATENTSCOPE COVID-19 INDEX - World Intellectual Property Organization (WIPO): WIPO’s PATENTSCOPE provides information about patents and patent applications. The new COVID-19 search facility provides curated information about technologies relevant for COVID-19. Information is currently available for different types of technology, including diagnostics, medical devices, medical treatment, personal protective equipment, among others.

  • Medicines Patents and Licenses Database (MedsPaL): MedsPaL provides information on the patent and licensing status of selected medicines in low- and middle-income countries. It includes some of the medicines currently being used and tested for COVID-19, such as remdesivir, lopinavir and ritonavir.

Patent Pools, Licensing, Access Provisions

 

  • WHO COVID-19 Technology Access Pool (C-TAP): C-TAP was launched in May 2020 by WHO, in partnership with the Government of Costa Rica, under a global Solidarity Call to Action, endorsed by nearly 40 member states. It provides a centralized space for developers of COVID-19 technologies to voluntarily share intellectual property, knowledge and data. The first license to C-TAP was announced in November 2021, with the Spanish National Research Council (CSIC) for a COVID-19 serological antibody technology.

  • Medicines Patent Pool (MPP) - COVID-19: MPP is a patent pool operating as a voluntary licensing mechanism through partnerships with originator pharmaceutical companies and generic manufacturers. It has expanded its original mandate to include COVID-19-related health technologies. The COVID-19 overview page provides information on MPP’s activities in this area, which includes licensing agreements with MSD for the drug molnupiravir and with Pfizer for its antiviral treatment candidate PF-07321332.

  • OPEN Covid Pledge: The Open COVID Pledge calls on organizations around the world to make their patents and copyrights freely available in the fight against the COVID-19 pandemic. It includes sample languages of commitments to making intellectual property relevant to COVID-19 freely available and information on licenses taken under the pledge.

  • COVID-19 Technology and Access Framework: Licensing principles to technologies developed at universities to maximize access to innovations. Initially signed by Harvard University, Massachusetts Institute of Technology and Stanford University, with additional signatories and open for endorsement.

Compulsory Licenses and Related Legislative Developments

 

  • Medicines Law & Policy TRIPS Flexibilities Database: The TRIPS Flexibilities Database contains instances when authorities have invoked, planned to invoke, or have been asked to invoke a TRIPS flexibility for public health reasons, in particular to assure access to medicines. The flexibilities included in the database are: compulsory licensing, including public non-commercial use (TRIPS art. 31), patent exceptions (TRIPS art. 30), the Least Developed Country transition provisions (Paragraph 7 of the Doha Declaration on TRIPS and Public Health) and parallel import (Paragraph 5(d) Doha Declaration. It contains filters by disease, including COVID-19.

  • Hungary: In December 2020, the Hungarian Intellectual Property Office issued three compulsory licenses for domestic use of remdesivir. Source: WTO - COVID-19 and trade - Hungary

  • France: On March 23, 2020, France passed the Emergency Law No 2020-290 to combat the COVID-19 epidemic, which introduced a new article into the public health code (Article L3131-15) giving extraordinary powers to the Prime Minister including to issue compulsory licences bypassing the general provisions in the Intellectual Property Code.

  • Canada: On March 25, 2020, Canada approved a change in its IP law to facilitate the process to issue compulsory licenses in the event of a public health crisis. The new provision allows the government to issue a compulsory license and negotiate its terms, including compensation, after.

  • Colombia: On March 25, 2020, Colombia approved a decree allowing the Ministry of Health to declare of public interest all medicines, medical devices, vaccines and other health technologies related to COVID19. The declaration of public interest is a necessary step prior to the grant of a compulsory license. The decree also the flexibilization of the rules regarding registration and importation of health technologies in the country.

  • Brazil: In April 2021, Brazil amended the provisions related to compulsory license for health emergencies and public interest in its patent law (articles 71 and 71-A, Law 9279/96, amended by Law 14200/21).

Patent Oppositions and Revocations


Companies Announcements

 

  • Abbvie: Following the compulsory license issued by Israel, AbbVie announced that it will not enforce its exclusivity rights over the drugs lopinavir and ritonavir, not only for its use on COVID-19 but for any use, anywhere in the world. Official document: Not available. The Medicines Patents and Licenses Database (MedsPaL) shows a Commitment not to enforce LPV/r or Ritonavir patents.

  • Gilead: Statement on Request to Rescind Remdesivir Orphan Drug DesignationThe company obtained orphan drug designation for remdesivir by the U.S. Food and Drug Administration, which grants a 7-year period of market exclusivity in the country. After intense criticism, Gilead requested to rescind the orphan drug designation. The company still holds patents in many countries for the drug, with grants exclusivity over its production and commercialization.

  • Roche: After the European Commission consideration to intervene in Roche due to a lack of capacity to produce enough tests for COVID-19, the company announced it will provide information for the production of a testing solution (lysis buffer) if laboratories ask for it.

    • Official document: Not available.

    • News report: here.

  • Medtronic: The company granted an open global license for the manufacturing of ventilators.

  • Moderna: The company announced that "while the pandemic continues" it "will not enforce COVID-19 related patents against those making vaccines intended to combat the pandemic" and that the company is willing to license upon request their intellectual property for COVID-19 vaccines for the post-pandemic period. The statement includes a list of selected US patents relevant to the mRNA-1273 vaccine against COVID-19. 

IPRs Infringement Allegations Cases

TRIPS Waiver Proposal

PRICING, PROCUREMENT, DISTRIBUTION AND MANUFACTURING

  • COVID-19 Vaccine Market Dashboard: UNICEF's interactive tool providing information on the COVID-19 vaccine market, including information on the global reported production capacity and publicly announced bilateral and multilateral supply agreements and price points.

Distribution

Manufacturing

  • VAXMAP: An open source-based map of COVID-19 candidate vaccines and manufacturing capacity. Compiled and maintained by the Third World Network.

Pricing

  • FIND. GeneXpert Negotiated Prices: The Foundation for Innovative New Diagnostics (FIND) provides information about the prices of the test GeneXpert sold by the company Cepheid. GeneXpert is currently being used for COVID-19 as well.

OTHER

  • ITPC COVID-19 Timeline: A resource by ITPC - International Treatment Preparedness Coalition providing chronologic summary information on the main topics related to the COVID-19 pandemic regarding epidemiology, natural historic, policy/access, testing/prevention, treatment, and vaccines.

  • WEMOS - Covid-19 initiatives: WEMOS provides an overview and critical review of a wide variety of initiatives taken by different public institutions to make access to Covid-19 innovations more equitable.

 
 
 
 
 
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.